NextCell Pharma: Our thoughts ahead of the phase ll readout - Redeye

Redeye comments on NextCell ahead of the ProTrans-Young Phase II readout expected in September. The data cut covers one-year results for the full 60-patient trial population and two-year results for the older cohort. The latter offers insight into whether the "honeymoon effect" could explain last year's inconclusive interim.

Länk till analysen i sin helhet: https://www.redeye.se/research/1185304/nextcell-pharma-our-thoughts-ahead-of-the-phase-ll-readout?utm_source=finwire&utm_medium=RSS